Company overview
Atinary provides an AI-driven R&D platform called SDLabs that integrates machine learning optimizers, data analytics, and visualization to accelerate experiment design and optimization in life sciences and pharma. The platform supports Self-Driving Labs with closed-loop Design-Make-Test-Analyze-Learn cycles, automating multi-objective optimization for process chemistry, small molecule synthesis, and catalyst development. It combines human judgment with AI and robotics from partners like ABB, Agilent, and Chemspeed for faster, scalable R&D.
Atinary is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include self-driving labs, ai r&d platform, pharma optimization, machine learning labs, process chemistry ai.
Structured facts
- Website
- https://atinary.com
- Markets served
- United States & Americas
- Keywords
- self-driving labs, ai r&d platform, pharma optimization, machine learning labs, process chemistry ai
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What core capabilities does Atinary offer for pharma R&D?
- Atinary's SDLabs platform delivers AI-driven optimization via machine learning, data analytics, visualization, and closed-loop DMTA+L cycles for experiment design, execution, analysis, and learning in process chemistry and small molecule synthesis.
- What geographies does Atinary serve?
- Atinary operates facilities in Boston (USA) and Basel (Switzerland), with a hardware-agnostic platform deployable in customer labs worldwide.
- Is Atinary's platform compatible with lab robotics and regulatory standards?
- Yes, it integrates with robotics and instruments from ABB, Agilent, Bruker, Chemspeed, and METTLER TOLEDO, supporting no-code AI for compliant, scalable lab automation in pharma R&D.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
